Cell therapy has produced some of the most remarkable clinical outcomes in the history of medicine. Patients with relapsed or refractory blood cancers – once facing grim odds – are achieving durable remissions. The science is extraordinary. But the story doesn’t end there, and for most of the world’s patients, it hasn’t really begun.
The uncomfortable truth is this: the therapies working in the lab and the clinic are still out of reach for many people who need them. And that gap isn’t closing fast enough.
A Global Access Crisis in Plain Numbers
A landmark 2026 study published in Blood examined CAR-T therapy access across G20 nations and found that fewer than half of FDA-approved CAR-T indications are publicly reimbursed – even among wealthy countries. Only high-income nations provide meaningful public coverage, and no middle-income country has achieved it at scale, with China being a notable exception [1].
China’s position as an outlier is worth examining. With over 200 cell therapy clinical trials registered between 2014 and 2024 – and a peak of 61 trials in 2023 alone – China has built genuine momentum [2]. Domestic companies are beginning to localize key manufacturing inputs, from viral vectors to automated cell preparation systems, driving costs down toward a range where national reimbursement becomes conceivable. One emerging developer is targeting a CAR-T price point of approximately ¥200,000 (~$28,000 USD) – a fraction of the million-yuan price tags currently on the market [1]. That’s not a solved problem, but it’s a proof of concept that cost reduction is achievable through intentional engineering and supply chain design.
The rest of the world needs to take note.
Where the Costs Actually Come From
Understanding the affordability problem requires understanding where money gets spent – and lost – in cell therapy manufacturing. It’s not one thing. It’s the accumulated weight of many.
Equipment is a starting point. Historically, fully automated cell preparation systems have been dominated by a small number of suppliers, with single-use consumable costs running into the tens of thousands of dollars per patient [1]. Viral vectors, activation reagents, and other critical materials have been similarly concentrated, leaving developers with little leverage and less flexibility.
Then there’s the manufacturing process itself. Traditional autologous cell therapy – where a patient’s own cells are extracted, engineered, and reinfused – is highly manual, highly variable, and time-consuming. A single instrument may only support production for a few dozen patients per year. Each manual step introduces variability, each open manipulation carries contamination risk, and each deviation from protocol can mean a batch loss or a delayed treatment. For a patient who has tried everything and who is running out of time, that is not a theoretical problem.
The result: high cost of goods, long vein-to-vein timelines, and a manufacturing model that struggles to scale.
Automation is Part of the Answer – But Not Just Any Automation
This is where the conversation often gets oversimplified. “Automate it” sounds like an obvious solution, until you realize that the wrong kind of automation can lock developers into rigid workflows, proprietary consumables, and systems that don’t translate across therapy types or scales.
What the industry needs is automation designed for flexibility: systems that adapt to a developer’s process, not the other way around. Closed-system automation reduces contamination risk and supports regulatory compliance without sacrificing the ability to customize protocols. Modular architectures allow teams to start where they are and scale as their programs grow, without overhauling everything at each transition stage. Open platforms – without locked software or hidden licensing restrictions – give developers the freedom to integrate their own materials, workflows, and IP.
Importantly, early automation pays compounding dividends. When process optimization happens at the research and early clinical stage – not retrofitted at commercial scale – teams de-risk manufacturing before it becomes expensive to change. Errors caught early don’t become regulatory issues later. Quality that is built in from the start is cheaper than quality corrected down the line.
This is the logic behind the broader push to automate earlier and more intelligently, as CellBri has presented in earlier posts: Bridging Innovation and Scalable Cell Therapy Production [4] and What Does “Automated Your Way” Mean? [5])
The Regulatory Tailwind
Combined with faster development timelines enabled by smarter automation and universally accessible consumables, these changes could meaningfully compress the path from clinical proof-of-concept to approved product.
There is also reason for cautious optimism on the regulatory front. In January 2026, the FDA issued updated guidance relaxing certain chemistry, manufacturing, and control (CMC) requirements for cell and gene therapy products [3]. Among the changes: a more flexible standard for manufacturing comparability data as products move through clinical phases, the ability to revisit product release specifications post-approval based on real-world manufacturing experience, and, significantly, the elimination of the requirement to supply three process performance qualification (PPQ) lots for process validation [3].
These are meaningful concessions to the realities of cell therapy manufacturing. They reflect a regulatory body that is listening to what developers have been saying for years: that the uniquely complex, individualized nature of these therapies demands standards that accommodate, rather than impede, innovation.
What Still Needs to Change
Regulatory flexibility and better automation are necessary but not sufficient conditions. The field also needs:
- Consumable independence. Developers should not be captive to proprietary supply chains for basic reagents and single-use materials. Open-platform manufacturing ecosystems – where teams can source and switch materials without overhauling an entire process – are essential to driving lasting cost reduction [5].
- Broader indication development. As clinical data accumulates in autoimmune diseases and eventually solid tumors, the patient populations who can benefit from cell therapy will grow [2]. A larger market, with more products moving through the pipeline, creates the volume economics that make cost reduction possible.
- Geographic diversification. The concentration of clinical trials and manufacturing expertise in a handful of cities (whether Shanghai and Beijing in China, or major academic medical centers in the US) limits both trial representativeness and the practical ability to treat patients closer to where they live [2]. Distributed manufacturing capacity, supported by scalable automation, is part of the solution to this ongoing disparity.
The Bigger Picture
Cell therapy works. The clinical evidence is now substantially clear. What remains in dispute is whether the industry can build the infrastructure – manufacturing, regulatory, economic, and logistical – to make these therapies available to more than a privileged few.
The innovations happening right now – from China’s cost-reduction engineering [2] to the FDA’s updated flexibility framework [3] to the next generation of automated platforms [4, 5] – are signs that the industry is taking this challenge seriously. Progress is real. But the urgency is greater.
Every year that a potentially curative therapy remains inaccessible is a year that patients – many with no other options – go without it. That should be enough motivation for everyone in this industry to keep pushing.
Follow us on LinkedIn to stay connected as we continue to push the future of cell therapy manufacturing.
References
[1] Ge, A. Y., Feldman, W. B., Kaiser, M. F., Rejeski, K., Iacoboni, G., Narula, G., Chan, J. Y., Dickinson, M. J., Kesselheim, A. S., & Scheffer Cliff, E. R. (2026). Global access to commercial CAR T-cell therapies: A cross-sectional study of health technology assessment across the G20 countries. Blood, 147(14), 1521–1531. https://doi.org/10.1182/blood.2025030872
[2] Shi, W., Du, C., Chen, Z., Guo, W., Li, F., Zou, Q., Feng, S., Cai, L., & Yu, Q. (2025). Current progress of cell therapy clinical trials in China in 2014–2024. BioMed Research International, 2025, Article 1901024. https://doi.org/10.1155/bmri/1901024
[3] Daughtrey, N. (2026, February 12). Reforms to FDA requirements for cell and gene therapy products. Big Molecule Watch. https://www.bigmoleculewatch.com/2026/02/12/reforms-to-fda-requirements-for-cell-and-gene-therapy-products/
[4] (2025, December). Bridging innovation and scalable cell therapy production. The CellBrief. https://cellbri.com/bridging-innovation-and-scalable-cell-therapy-production/
[5] (2025, December). What does “Automated Your Way” mean? The CellBrief. https://cellbri.com/what-does-automated-your-way-mean/